Cystic Fibrosis News and Research

Latest Cystic Fibrosis News and Research

Vertex Pharmaceuticals plans proof-of-concept clinical trials in RA and epilepsy

Vertex Pharmaceuticals Incorporated today provided an update on key 2010 business priorities in conjunction with the 28th Annual J.P. Morgan Healthcare Conference in San Francisco. The company also discussed recent progress in its lead development programs in hepatitis C virus (HCV) infection and cystic fibrosis (CF) and outlined proof-of-concept clinical trials planned in other serious diseases for 2010.

11 Jan 2010

CLSI’s document provides revised guidelines for screening cystic fibrosis

Clinical and Laboratory Standards Institute (CLSI) recently published Sweat Testing: Sample Collection and Quantitative Chloride Analysis; Approved Guideline—Third Edition (C34-A3). This document addresses appropriate methods of collection and analysis, quality control, and the evaluation and reporting of sweat test results for the diagnosis of cystic fibrosis.

7 Jan 2010

Scientists develop mucus-penetrating biodegradable nanoparticles to deliver drugs over time

Johns Hopkins University researchers have created biodegradable nanosized particles that can easily slip through the body's sticky and viscous mucus secretions to deliver a sustained-release medication cargo.

5 Jan 2010

Research shows licorice root might be effective in fighting antibiotic-resistant infections

A team of scientists from the University of Texas Medical Branch and Shriners Hospitals for Children show how a compound from licorice root (glycyrrhizin from Glycyrrhiza glabra) might be an effective tool in battling life-threatening, antibiotic-resistant infections resulting from severe burns.

5 Jan 2010

Discovery of key process in bacterial infection could lead to new drug targets to prevent infection

Bacteria can swim, propelling themselves through fluids using a whip-like extension called a flaggella. They can also walk, strolling along solid surfaces using little fibrous legs called pili. It is this motility that enable some pathogenic bacteria to establish the infections - such as meningitis - that cause their human hosts to get sick or even die.

4 Jan 2010

WDI utilizes DXA analysis for fitness and weight management programs

Women's Digital Imaging of Ridgewood (WDI), has begun using Dual Energy X-ray Absorptiometry (DXA), a technology developed to screen for osteoporosis (bone loss), to measure body fat in patients who want a more accurate method of establishing goals and measuring results for weight management and fitness programs.

4 Jan 2010

Disinfectants can promote growth of antibiotic-resistant bacteria

Using disinfectants could cause bacteria to become resistant to antibiotics as well as the disinfectant itself, according to research published in the January issue of Microbiology.

28 Dec 2009

Researchers identify new method to tackle bacterial infections

Researchers from the University of Groningen have clarified the structure of an enzyme that disturbs the communication processes between bacteria. By doing so they have laid the foundations for a new method of tackling bacterial infections such as cystic fibrosis.

22 Dec 2009

New ways of treating infections identified by researchers at Binghamton University

Researchers at Binghamton University, State University of New York, have identified three key regulators required for the formation and development of biofilms. The discovery could lead to new ways of treating chronic infections.

19 Dec 2009

Researchers discover how protein can be controlled and under what circumstances it can go awry

A team of researchers studying the protein that, when defective or absent, causes cystic fibrosis (CF) has made an important discovery about how that protein is normally controlled and under what circumstances it might go awry.

18 Dec 2009

NanoBio, GSK partner to develop and commercialize novel cold sore treatment compound

GlaxoSmithKline plc and NanoBio Corporation today announced an exclusive licensing agreement in the United States and Canada for the over-the-counter (OTC) use of NB-001, a novel, patented compound representing the next advance in the treatment of cold sores. Developed by NanoBio, NB-001 provides significant antimicrobial activity against the virus that causes cold sores, herpes labialis.

16 Dec 2009

BUSM Pulmonary Center awarded $1.4M grant to derive stem cells and lung progenitors from lung disease patients

Boston University School of Medicine's (BUSM) Pulmonary Center has received a two-year $1.4 million grant from the National Heart, Lung, and Blood Institute to derive stem cells and lung progenitors from patients with lung disease.

16 Dec 2009

Carrier screening reduces CF birth rates in northeast Italy

An increase in the number of screened carriers for cystic fibrosis (CF) was associated with a decrease in the number of children born with CF in northeast Italy, according to a study in the December 16 issue of JAMA.

16 Dec 2009

Findings raise new hope for asthma and chronic obstructive pulmonary disease

A new study involving data from more than 20,000 individuals has uncovered several DNA sequences linked to impaired pulmonary function. The research, an analysis that combined the results of several smaller studies, provides insight into the mechanisms involved in reaching full lung capacity.

15 Dec 2009

Tel Aviv University researchers unravel the mysteries of DNA packaging

The RNA "spools" that make up DNA in our genes need careful editing, too. Genes are composed of meaningful sequences, called exons, separated by meaningless junk sections called introns.

15 Dec 2009

Several DNA sequences linked to impaired pulmonary function, uncovers new study

14 Dec 2009

FDA Drugs Advisory Committee recommends approval for Gilead Sciences' aztreonam for inhalation solution

Gilead Sciences, Inc. today announced that the Anti-Infective Drugs Advisory Committee of the U.S. Food and Drug Administration (FDA) has recommended that aztreonam for inhalation solution be approved for the treatment of infections due to Pseudomonas aeruginosa (P. aeruginosa) in patients with cystic fibrosis (CF).

11 Dec 2009

New data from NanoBio's nanoemulsion-based adjuvant platform to be presented

NanoBio Corporation announced today that its CEO and Founder, James R. Baker, Jr., M.D., will present new data from studies of its nanoemulsion-based adjuvant platform during the World Influenza Congress, taking place from December 7-9, 2009 in Brussels, Belgium.

8 Dec 2009

New approach to protein misfolding may lead to novel therapies for a number of diseases

In an encouraging new development, a team led by Scripps Research Institute scientists has restored partial function to lung cells collected from patients with cystic fibrosis. While there is still much work to be done before the therapy can be tested in humans, the discovery opens the door to a new class of therapies for this and a host of other chronic diseases.

7 Dec 2009

Vertex Pharmaceuticals reports underwriters purchase additional stock at 38.50 per share

Vertex Pharmaceuticals Incorporated today announced that the underwriters of its public offering have exercised in full their option to purchase an additional 1,500,000 shares of common stock at the public offering price of $38.50 per share.

5 Dec 2009

Cystic Fibrosis News and Research

Latest Cystic Fibrosis News and Research

Vertex Pharmaceuticals plans proof-of-concept clinical trials in RA and epilepsy

CLSI’s document provides revised guidelines for screening cystic fibrosis

Scientists develop mucus-penetrating biodegradable nanoparticles to deliver drugs over time

Research shows licorice root might be effective in fighting antibiotic-resistant infections

Discovery of key process in bacterial infection could lead to new drug targets to prevent infection

WDI utilizes DXA analysis for fitness and weight management programs

Disinfectants can promote growth of antibiotic-resistant bacteria

Researchers identify new method to tackle bacterial infections

New ways of treating infections identified by researchers at Binghamton University

Researchers discover how protein can be controlled and under what circumstances it can go awry

NanoBio, GSK partner to develop and commercialize novel cold sore treatment compound

BUSM Pulmonary Center awarded $1.4M grant to derive stem cells and lung progenitors from lung disease patients

Carrier screening reduces CF birth rates in northeast Italy

Findings raise new hope for asthma and chronic obstructive pulmonary disease

Tel Aviv University researchers unravel the mysteries of DNA packaging

Several DNA sequences linked to impaired pulmonary function, uncovers new study

FDA Drugs Advisory Committee recommends approval for Gilead Sciences' aztreonam for inhalation solution

New data from NanoBio's nanoemulsion-based adjuvant platform to be presented

New approach to protein misfolding may lead to novel therapies for a number of diseases

Vertex Pharmaceuticals reports underwriters purchase additional stock at 38.50 per share

Fluidics in Modern Healthcare & Medical Device Innovation

Scaling 3D biology: Automation, imaging, and the future of high-throughput research

How does norepinephrine influence anxiety-related behaviours?

Cystic Fibrosis News and Research

Latest Cystic Fibrosis News and Research

Fluidics in Modern Healthcare & Medical Device Innovation

Scaling 3D biology: Automation, imaging, and the future of high-throughput research

How does norepinephrine influence anxiety-related behaviours?

Newsletters you may be interested in